StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code SR-GT1) Aimed at Curative Treatment of Dystrophic Epider10/16TDnetPDF(292KB)
StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Psorias10/1TDnetPDF(146KB)
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator9/26TDnetPDF(137KB)
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company's Executive Officers, Employees, and External Collaborators9/18TDnetPDF(171KB)
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees9/10TDnetPDF(177KB)
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2025 [Japanese GAAP]9/10TDnetPDF(546KB)
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator9/10TDnetPDF(229KB)
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors9/10TDnetPDF(206KB)